CALL - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Bid/Ask 01:15:17 2024-05-21 pm EDT | ||
| 21.33 EUR / 21.78 EUR | +2.35% |
|
| 1 month | +6.04% | ||
| 3 months | +8.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 21.21 | +0.71% |
| 24-05-17 | 21.06 | -0.47% |
| 24-05-16 | 21.16 | +0.28% |
| 24-05-15 | 21.1 | +0.19% |
| 24-05-14 | 21.06 | +0.48% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 03:45 am EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN8X4Z |
| ISIN | DE000VN8X4Z7 |
| Date issued | 2017-04-10 |
| Strike | 123.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.02 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.37 € |
|---|---|
| Lowest since issue | 0.065 € |
| Spread | 0.45 € |
| Spread % | 2.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
